arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CAPRICOR THERAPEUTICS, INC.

CAPR
$8.64 ▼ -0.30 (-3.36%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
21 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

CAPRICOR THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $401.6M
Dividend Yield —
Revenue Growth N/M
Op. Margin None
ROIC -35.4% ↘
FCF / Share $-1.56 ↘
Trailing P/E —
Price / Book 1.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

21-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-105.04M
↓ -159.6% —
Operating Margin Operating profit as % of sales
-191.1%
↓ -99.9% —
FCF / Share Free cash flow per share
$-1.56
↓ -33.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
21
Cash Quality ↓
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 21 years · 81 quarters